Offer for Sale Rs. 4326cr

The funds collected from the Offer for Sale will not be used by the company.

Achieve the benefits of listing the equities on the stock exchange

Mankind Pharma develops, manufactures, and markets a wide range of pharmaceutical formulations in acute and chronic therapeutic areas, as well as several consumer healthcare items.

They are focused on the domestic market, with India accounting for 98% of their income.

​The pharmaceuticals business accounts for 90% of its revenue, while the consumer business accounts for 10%.

They have created 36 brands in the pharmaceutical business, each of which has reached over 50 crore in domestic sales in the last 12 months till December 2022.

In 9 months till December 2022, the company reported a revenue of Rs. 6697 crore and a net profit of Rs. 1016 crore.

​In FY22, the company reported a revenue of Rs. 7782 crore, compared to Rs. 6214 crore of FY21.

The company reported net profit of Rs 1453 crore in FY2022, compared to Rs 1293 crore, a growth of 12.4 per cent.

In FY22, the company reported a RONW of 23.3%, down from 26.8% in FY21 and 29.6% in FY20.